TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04968392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: 20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: 20 mL of 0.25% levobupivacaine plus 1 mL normal saline
Study: NCT04458740

Intervention type: OTHER
Intervention: biographical interviews
Description: A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual

Intervention type: OTHER
Intervention: biographical interviews
Description: A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
Study: NCT04457986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector spina plane block (ESP)
Description: Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified thoracolumbar interfacial plane block (MTI)
Description: Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient controlled analgesia (IV-PCA)
Description: Patient will receive intravenous patient controlled analgesia with tramadol
Study: NCT00658489

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
Study: NCT02101398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eldith DC-stimulator, configuration F7A
Description: tDCS will be delivered during a 20 minutes speech-language therapy session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eldith DC-stimulator, configuration F7C
Description: tDCS will be delivered during a 20 minutes speech-language therapy session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eldith DC-stimulator, configuration T5A
Description: tDCS will be delivered during a 20 minutes speech-language therapy session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eldith DC-stimulator, configuration T5C
Description: tDCS will be delivered during a 20 minutes speech-language therapy session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eldith DC-stimulator, configuration Sham
Description: Sham tDCS will be delivered during a 20 minutes speech-language therapy session
Study: NCT03853044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
Study: NCT02907658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT intervention group
Description: The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
Study: NCT03341637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) subcutaneous injection
Study: NCT02188719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
Study: NCT02661152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimorazole
Description: Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
Study: NCT02673983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness biopsy
Study: NCT02347592

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-locating Catheter
Description: Procedure/Surgery necessary if obstruction occurs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: straight Tenckhoff
Description: Procedure/Surgery necessary if obstruction occurs
Study: NCT02188719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsies
Description: Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
Study: NCT01682109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Study: NCT03855943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Computer Program
Description: Training with a personalized computerized inhibitory training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
Study: NCT03293121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength and Coordination Training
Description: Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength \& coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
Study: NCT02217618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Study: NCT03579758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT03470350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: treatment with capecitabine and galunisertib
Study: NCT01684670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech sessions
Description: Subjects will be instructed to use clear speech and increased effort when speaking.
Study: NCT01868828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAD
Description: Induction Therapy of PAD for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCD
Description: Induction Therapy of VCD for 4 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Not suitable for transplant patients will continue accept treatment for 8 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Not suitable for transplant patients will continue accept treatment for 8 cycles.
Study: NCT03443687

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Physical Therapy
Description: Pelvic floor exercises for 3 months under instruction of physical therapist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Biofeedback
Description: Pelvic floor exercises for 3 months using biofeedback device
Study: NCT03775993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human growth hormone
Description: Administration of growth hormone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study: NCT02764996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT01196195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra dosed once daily
Description: Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kaletra dosed twice daily
Description: Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
Study: NCT04023292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
Study: NCT04161209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single dose administration of citalopram (20mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose placebo tablet
Study: NCT05771532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Received the GS-SHEP
Description: The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet). GS-SHEP effectiveness was examined using a self-report instrument to measure background information and three dependent variables: sexual knowledge, sexual attitudes, and sexual self-efficacy.
Study: NCT00441766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Part A: placebo capsule every 12 hours for 4 weeks
Study: NCT00649350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 750 mg
Description: 750mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage XR 750 mg
Description: 750mg, single dose fed
Study: NCT02748681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP AirSense™ 10(Resmed)
Description: AutoSet CPAP without telemedicine monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP AirSense™ 10(Resmed)
Description: AutoSet CPAP without telemedicine monitoring
Study: NCT02640027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cast removal at home using a telemedicine tool
Description: Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
Study: NCT02188719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsies
Description: Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver biopsies
Description: Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
Study: NCT01306747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Stanford Chronic Pain Self-Management Programme
Description: The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
Study: NCT00369837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Description: Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
Study: NCT02188719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
Study: NCT02197572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapanisertib capsules.
Study: NCT03758807

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual Therapy with Traditional Biomechanical Explanation
Description: Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy with Neuroplastiicity Explanation
Description: Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
Study: NCT04593121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB107
Description: Administered as specified in the treatment arm.
Study: NCT02188719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
Study: NCT03077113

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 4-D CT Scan
Description: The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SPECT-CT Scan
Description: It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
Study: NCT01557764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study: NCT02861755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Skills Training
Description: Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-week Emotion Reporting
Study: NCT00676793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Four 200mg capsules daily taken with a meal, for the duration of the study.
Study: NCT04496648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention with drug-eluting stents and modern techniques

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-percutaneous coronary intervention
Description: Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
Study: NCT03746067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-134
Description: 5 mg, 10 mg, or 20 mg oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo oral solution
Study: NCT01992848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood sampling
Description: 40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-day food diary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 week UV dosimeter
Description: To be worn on outerwear for one week week prior to attendance for pQCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Peripheral Quantitative Computed Tomography of the radius
Description: To be performed within one month of attendance for CT coronary angiography
Study: NCT04269655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud-Based Continuous Glucose Monitoring
Description: The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
Study: NCT01899677

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: 0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: symbiotic
Description: Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
Study: NCT03841487

Intervention type: DEVICE
Intervention: Aspiration thrombectomy
Description: In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
Study: NCT04150562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.